• HBM Holdings appointed Lloyd Klickstein as scientific advisor for immunology on June 28, 2026.
• Klickstein is CEO of Koslapp Therapeutics.
• He co-founded Versanis Bio, held senior roles before its acquisition by Eli Lilly.
• He previously served as chief innovation officer at Adicet Bio, chief scientific officer at resTORbio, spent over a decade at Novartis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606282127PR_NEWS_USPR_____CN93818) on June 29, 2026, and is solely responsible for the information contained therein.